Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Presentation

Interim Safety and Efficacy Results From a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)

Download PDF